Literature DB >> 22785241

Etiologic diagnosis of nonsyndromic genetic hearing loss in adult vs pediatric populations.

Peter J King1, Xiaomei Ouyang, Lilin Du, Denise Yan, Simon I Angeli, Xue Zhong Liu.   

Abstract

OBJECTIVES: Determine the diagnostic yield of a shared genetic testing algorithm in adult and pediatric populations with sensorineural hearing loss (SNHL) and recommend effective testing strategies to evaluate for genetic causes of deafness in patients presenting with idiopathic sensorineural hearing loss. STUDY
DESIGN: Hospital-based cohort study.
SETTING: University of Miami outpatient otology clinics between 2001 and 2010.
SUBJECTS: Two hundred twenty-one adult and 163 pediatric patients with nonsyndromic sensorineural hearing loss.
METHODS: Peripheral blood samples were screened for mutations in GJB2 and GJB6 and mitochondrial DNA mutations 1555A>G, 7444G>A, and 3243A>G. Audiometric data and family history were also collected.
RESULTS: GJB2/GJB6-related deafness was diagnosed in 23 of 163 pediatric patients (14%) compared with only 3 of 221 adults (1%). All adults had a family history of hearing loss, and 2 patients noted deafness onset at birth. Nineteen GJB2 mutations were identified with 35delG the most common mutation. The 35delG homozygous state was the most common pathogenic genotype (54%). Mitochondrial DNA (mtDNA) mutations were found in 6 adult probands (3%). No mtDNA mutations were found in pediatric patients.
CONCLUSION: Testing for common GJB2/GJB6 mutations in pediatric patients has considerable value in establishing an etiologic diagnosis for SNHL. Similar testing in adults is of very low yield except perhaps in cases of early-onset SNHL or strong family history. Mitochondrial DNA testing should be considered in adults with idiopathic SNHL.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22785241      PMCID: PMC4511085          DOI: 10.1177/0194599812453553

Source DB:  PubMed          Journal:  Otolaryngol Head Neck Surg        ISSN: 0194-5998            Impact factor:   3.497


  12 in total

1.  Prevalence of mitochondrial gene mutations among hearing impaired patients.

Authors:  S Usami; S Abe; J Akita; A Namba; H Shinkawa; M Ishii; S Iwasaki; T Hoshino; J Ito; K Doi; T Kubo; T Nakagawa; S Komiyama; T Tono; S Komune
Journal:  J Med Genet       Date:  2000-01       Impact factor: 6.318

Review 2.  Newborn hearing screening--a silent revolution.

Authors:  Cynthia C Morton; Walter E Nance
Journal:  N Engl J Med       Date:  2006-05-18       Impact factor: 91.245

3.  Clinical comparison of hearing-impaired patients with DFNB1 against heterozygote carriers of connexin 26 mutations.

Authors:  Michael Lipan; Xiaomei Ouyang; Denise Yan; Simon Angeli; Li Lin Du; Xue-Zhong Liu
Journal:  Laryngoscope       Date:  2011-02-01       Impact factor: 3.325

4.  Coenzyme Q-10 treatment of patients with a 7445A--->G mitochondrial DNA mutation stops the progression of hearing loss.

Authors:  Simon I Angeli; Xue Z Liu; Denise Yan; Thomas Balkany; Fred Telischi
Journal:  Acta Otolaryngol       Date:  2005-05       Impact factor: 1.494

5.  Carrier rates in the midwestern United States for GJB2 mutations causing inherited deafness.

Authors:  G E Green; D A Scott; J M McDonald; G G Woodworth; V C Sheffield; R J Smith
Journal:  JAMA       Date:  1999-06-16       Impact factor: 56.272

6.  Change in prevalence of hearing loss in US adolescents.

Authors:  Josef Shargorodsky; Sharon G Curhan; Gary C Curhan; Roland Eavey
Journal:  JAMA       Date:  2010-08-18       Impact factor: 56.272

7.  Novel mutations in the connexin 26 gene (GJB2) that cause autosomal recessive (DFNB1) hearing loss.

Authors:  P M Kelley; D J Harris; B C Comer; J W Askew; T Fowler; S D Smith; W J Kimberling
Journal:  Am J Hum Genet       Date:  1998-04       Impact factor: 11.025

8.  A diagnostic paradigm for childhood idiopathic sensorineural hearing loss.

Authors:  Diego A Preciado; Lynne H Y Lim; Aliza P Cohen; Colm Madden; David Myer; Chris Ngo; John K Bradshaw; Louise Lawson; Daniel I Choo; John H Greinwald
Journal:  Otolaryngol Head Neck Surg       Date:  2004-12       Impact factor: 3.497

Review 9.  Clinical aspects of hereditary hearing loss.

Authors:  Amit Kochhar; Michael S Hildebrand; Richard J H Smith
Journal:  Genet Med       Date:  2007-07       Impact factor: 8.822

10.  Familial progressive sensorineural deafness is mainly due to the mtDNA A1555G mutation and is enhanced by treatment of aminoglycosides.

Authors:  X Estivill; N Govea; E Barceló; C Badenas; E Romero; L Moral; R Scozzri; L D'Urbano; M Zeviani; A Torroni
Journal:  Am J Hum Genet       Date:  1998-01       Impact factor: 11.025

View more
  3 in total

1.  Spectrum of DNA variants for non-syndromic deafness in a large cohort from multiple continents.

Authors:  Denise Yan; Demet Tekin; Guney Bademci; Joseph Foster; F Basak Cengiz; Abhiraami Kannan-Sundhari; Shengru Guo; Rahul Mittal; Bing Zou; Mhamed Grati; Rosemary I Kabahuma; Mohan Kameswaran; Taye J Lasisi; Waheed A Adedeji; Akeem O Lasisi; Ibis Menendez; Marianna Herrera; Claudia Carranza; Reza Maroofian; Andrew H Crosby; Mariem Bensaid; Saber Masmoudi; Mahdiyeh Behnam; Majid Mojarrad; Yong Feng; Duygu Duman; Alex M Mawla; Alex S Nord; Susan H Blanton; Xue Z Liu; Mustafa Tekin
Journal:  Hum Genet       Date:  2016-06-25       Impact factor: 4.132

2.  MYO3A Causes Human Dominant Deafness and Interacts with Protocadherin 15-CD2 Isoform.

Authors:  M'hamed Grati; Denise Yan; Manmeet H Raval; Tom Walsh; Qi Ma; Imen Chakchouk; Abhiraami Kannan-Sundhari; Rahul Mittal; Saber Masmoudi; Susan H Blanton; Mustafa Tekin; Mary-Claire King; Christopher M Yengo; Xue Zhong Liu
Journal:  Hum Mutat       Date:  2016-02-16       Impact factor: 4.878

3.  Screening of genetic alterations related to non-syndromic hearing loss using MassARRAY iPLEX® technology.

Authors:  Maria Carolina Costa Melo Svidnicki; Sueli Matilde Silva-Costa; Priscila Zonzini Ramos; Nathalia Zocal Pereira dos Santos; Fábio Tadeu Arrojo Martins; Arthur Menino Castilho; Edi Lúcia Sartorato
Journal:  BMC Med Genet       Date:  2015-09-23       Impact factor: 2.103

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.